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Introduction
Dementia encompassing deteriorations in several cogni-
tive domains can be caused by a large variety of disorders, 
disturbing brain functions due to loss of synapses and 
neurons. Consensus criteria for the clinical diagnosis of 
major dementing disorders exist and have recently been 
revised [1]. Th  e combination of clinical data with 
biomarkers has improved the diagnostic accuracy of 
Alzheimer’s disease (AD) from 65% to between 92 and 
96%, while the sensitivity and speciﬁ   city versus other 
demen  tias are much lower. Fusion of the best cerebro-
spinal ﬂ  uid biomarkers and magnetic resonance imaging 
data will lead to a more precise diagnostic prediction [2].
Diagnostic guidelines for the neuropathological diag-
nosis of AD and other dementias rely on (semi)quanti-
tative and topographic assessment of morphological and 
bio/histochemical signposts; in particular, speciﬁ  c 
protein inclusions in neurons and glia [3]. Diagnostic 
criteria for AD – in addition to cut-oﬀ   values of senile 
plaques and tangles, their semiquantitative assessment 
and age adjustment in the Consortium to Establish a 
Registry for Alzheimer’s Disease protocol – include the 
topographic staging of neuritic AD pathology, re-
evaluated recently [4].
Th  e combination of the Consortium to Establish a 
Registry for Alzheimer’s Disease and the Braak scores in 
the National Institute of Aging–Reagan Institute criteria 
relates dementia to AD typical lesions with high, inter-
mediate and low likelihood [5]. Evaluation of the criteria 
showed their validity in AD – high lesion stages identi-
fying 54 to 97% of AD cases and eliminating between 62 
and 100% of nondemented subjects with low Braak 
stages, whereas only between 8 and 42% were identiﬁ  ed 
among non-AD neurodegenerative dementias [1].
Specifi  c problems in the diagnosis of Alzheimer’s 
disease
Th  e current algorithms for the neuropathological diag-
nosis of AD, based on assessment of plaques and tangles, 
despite reasonable interrater agreement when using 
standardized criteria, only consider the classical plaque 
and tangle phenotype of AD but do not recognize other 
subtypes.
Th  e plaque-predominant type with abundant amyloid 
plaques, with no or very little neuritic pathology restricted 
to the hippocampus and with abnormal phos  phory  lated 
tau in neocortical pyramidal cells, but lacking overt tangle 
formation, accounts for 3.5 to 8% of demented subjects 
over age 85 years [6]. Many of these cases are associated 
with cortical Lewy bodies, representing a speciﬁ  c type of 
dementia with Lewy bodies.
Tangle-predominant dementia occurring in the very 
old (age 80+ years) and accounting for 5 to 7% of dementia 
cases shows tau pathology often restricted to the limbic 
system, an absence of neuritic plaques, and no or very 
little (diﬀ  use) amyloid deposits. Since the tangles in this 
type react with three-repeat and four-repeat tau similar 
to those in classical AD, it could be considered a subtype 
of AD; tangle-predominant dementia, however, is clinically 
sometimes diﬀ  erent and associated with diﬀ  erent apolipo-
protein E genotypes [7].
Standard metrics for plaques and tangles are usually 
semiquantitative; good agreement was reached only 
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(Braak stage V to VI with absolute agreement 91%), while 
for mild stages the agreement was poorer [8], limiting the 
ability to make accurate correlation of antemortem 
cognitive status and pathology. Although the sensitivity 
and speciﬁ  city of the National Institute of Aging–Reagan 
Institute criteria are suggested to be 90%, only 30 to 57% 
of the brains of patients with a clinical diagnosis of 
probable AD show pure AD pathology [1]. Th  eir  predic-
tive value may thus be reduced to 38 to 44% [9]. In a 
retro  spective clinicopathological study of 1,700 demented 
persons (66% female; Mini-Mental State Examination 
score <20; mean age at death 84.3 to 6.0 years; 90% over 
age 70 years), AD-related lesions were present in 83.2%, 
but pure AD without other pathologies was present in 
only 42.0%, AD with other pathologies including mixed 
dementia in 41.2%, vascular dementia in 12.8%, other 
disorders in 4.1%, and negative pathology in 0.9% [10].
Although cognitively unimpaired subjects may show 
variable neocortical AD pathology, and although good 
correlations between the severity and extension of tau 
pathology and/or of β-amyloid load have been found, at 
least in those without superimposed other brain diseases 
[11], the distinction between physiological and patho-
logical aging (often but not consistently associated with 
cognitive decline) may be diﬃ   cult.  Speciﬁ  c  problems 
arise from considerable diﬀ   erences between genetic/
familial AD and sporadic AD [12] and between oldest-old 
patients and younger patients, with considerable diﬀ  er-
ences in both the intensity and distribution of AD 
pathology. Increased densities of neuritic plaques and 
tangles are absent in demented patients over age 90 years, 
with con  siderable overlap between demented and 
nondemented cases [13]. A high percentage of demented 
persons aged 80+ years do not meet the pathological 
criteria of AD or were classiﬁ  ed as dementia of unknown 
etiology [14]. In a prospective study of 180 demented 
patients (mean age 85 ± 3.4 years), autopsy showed AD in 
48%, AD with vascular pathology in 19%, vascular 
dementia in 11%, dementia with Lewy bodies in 9%, and 
dementia of unknown etiology in 13% (KA Jellinger, 
unpublished observations).
An important problem is the frequent presence of 
confounding processes in the aged brain that coexist with 
AD – such as cerebrovascular disease, Lewy body patho-
logy, argyrophilic grain disease, hippocampal sclerosis, 
and so forth – with about two-thirds of cases showing 
mixed pathologies (see [1,15]), which have, however, 
frequently been missed clinically and could not be 
identiﬁ  ed without neuropathological examination using 
modern biochemical and molecular-biological analyses 
[3,16]. Since 50 to 85% of the brains of oldest-old patients 
show cerebrovascular lesions, a speciﬁ  c problem is their 
impact in relation to AD pathology [15]. Th   e burden of 
vascular and AD-type pathologies are con  sidered 
independent of each other, and are consistent with an 
additive or synergistic eﬀ  ect of both types on cognitive 
impairment [1,17]. It should be borne in mind that all 
additional pathologies may interact, although their 
mutual impact often remains unclear.
Th  ere is increasing use of biochemical (and genetic) 
approaches for reﬁ  nement of diagnosis and analysis of 
the relevant contribution of diﬀ  erent disease processes to 
neurodegeneration of AD and other dementias [1,3,16,18]. 
Since the majority of degenerative dementing disorders 
are associated with intracellular and/or extracellular 
deposition of misfolded proteins (proteinopathies), most 
of them can be classiﬁ   ed and diagnosed by morpho-
logical, immunohistochemical and/or molecular-biological 
(neurochemical) identiﬁ   cation of these deposits repre-
sent  ing characteristic markers and signposts of particular 
disorders. Algorithms for the molecular-pathological 
classiﬁ   cation of sporadic (nongenetic/nonhereditary) 
forms of neurodegenerative dementias have been pro-
posed recently [3,16,18]. Since there is considerable 
clinical and morphological overlap between many of 
these disorders, however, the reliability and clinical 
relevance of the current diagnostic criteria need better 
qualiﬁ  cation and validation.
Conclusion
Although molecular genetics, biochemistry and animal 
models, at least in part reproducing the morphology of 
human AD and related disorders, have produced a large 
and convincing body of data on the pathogenesis and 
pathophysiology of the disease and have made an 
increasing contribution to postmortem studies of the 
cellular and molecular changes that underpin AD and 
other causes of dementia, the molecular backgrounds, 
the basic etiological factors, the pathogenic inter-
relationships of various concomitant pathologies, and the 
impact for an exact diagnosis of AD need further 
validation. Harmonized techniques are required to 
increase the accuracy and reproducibility of neuro-
pathological diagnosis as a basis for further successful 
treatment and neuroprotection.
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